Endocan: A novel biomarker for risk stratification, prognosis and therapeutic monitoring in human cardiovascular and renal diseases

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Bessa, J (Author) Other; Albino Teixeira, A (Author) Other; Marta R Couto (Author) FMUP; Sousa, T (Author) FMUP

Journal

Title: Clinica Chimica Acta

Vol. 509

Pages: 310-335

ISSN: 0009-8981

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 22 Citations

Scopus - 21 Citations

Other information

Authenticus ID: P-00S-J18

DOI: 10.1016/j.cca.2020.07.041

Abstract (EN): The vascular endothelium is localized at the interface between the blood and surrounding tissues, playing a pivotal role in the maintenance of tissue-fluid homeostasis and in the regulation of host defense, inflammation, vascular tone and remodeling, angiogenesis and haemostasis. The dysfunctional endothelium was shown to be implicated in the pathophysiology of several endothelial-dependent disorders, such as arterial hypertension, coronary artery disease, heart failure and chronic kidney disease, in which it is an early predictor of cardiovascular events. Endocan is a soluble dermatan sulphate proteoglycan mainly secreted by the activated endothelium. It is upregulated by several proinflammatory cytokines and proangiogenic factors and may itself contribute to the inflammatory status. In addition of being a surrogate marker of inflammation and endothelial dysfunction, it seems to be involved in the regulation of several proliferative and neovascularization processes. Therefore, its utility as a biomarker in a wide spectrum of diseases has been increasingly explored. Here, we review the current evidence concerning the role of endocan in several human cardiovascular and renal diseases, where it seems to be a promising biomarker for risk stratification, prognosis and therapeutic monitoring.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 26